Literature DB >> 7811058

Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes.

O Zelphati1, E Wagner, L Leserman.   

Abstract

Encapsulation of oligonucleotides in antibody-targeted liposomes (immunoliposomes) which bind to target cells permits intracellular delivery of the oligonucleotides. This approach circumvents problems of extracellular degradation by nucleases and poor membrane permeability which free phosphodiester oligonucleotides are subject to, but leaves unresolved the inefficiency of encapsulation of oligonucleotides in liposomes. We have coupled oligonucleotides to cholesterol via a reversible disulfide bond. This modification of oligonucleotides improved their association with immunoliposomes by a factor of about 10 in comparison to unmodified oligonucleotides. The presence of cholesteryl-modified oligonucleotides incorporated in the bilayer of liposomes did not interfere with the coupling of the targeting protein to the liposome surface. Free or cholesterol coupled oligonucleotides associated with liposomes and directed against the tat gene of HIV-1 were tested for inhibition of HIV-1 proliferation in acutely infected cells. We demonstrate that the cholesteryl-modified as well as unmodified oligonucleotides acquire the target specificity of the antibody on the liposome. Their antiviral activity when delivered into cells is sequence-specific. The activity of these modified or unmodified oligonucleotides to inhibit the replication of HIV was the same on an equimolar basis (EC50 around 0.1 microM). Cholesterol coupled oligonucleotides thus offer increased liposome association without loss of antiviral activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811058     DOI: 10.1016/0166-3542(94)90090-6

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

Authors:  B Bramlage; S Alefelder; P Marschall; F Eckstein
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

3.  Stepwise synthesis of RNA conjugates carrying peptide sequences for RNA interference studies.

Authors:  Anna Aviñó; Sandra M Ocampo; Clara Caminal; José Carlos Perales; Ramon Eritja
Journal:  Mol Divers       Date:  2009-02-03       Impact factor: 2.943

4.  Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139.

Authors:  Wanlop Weecharangsan; Bo Yu; Shujun Liu; Jiu Xia Pang; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Anticancer Res       Date:  2010-01       Impact factor: 2.480

Review 5.  Recent trends of polymer mediated liposomal gene delivery system.

Authors:  Shyamal Kumar Kundu; Ashish Ranjan Sharma; Sang-Soo Lee; Garima Sharma; C George Priya Doss; Shin Yagihara; Do-Young Kim; Ju-Suk Nam; Chiranjib Chakraborty
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

6.  Synthesis of a cholesteryl-HEG phosphoramidite derivative and its application to lipid-conjugates of the anti-HIV 5'TGGGAG³' Hotoda's sequence.

Authors:  Domenica Musumeci; Daniela Montesarchio
Journal:  Molecules       Date:  2012-10-22       Impact factor: 4.411

Review 7.  Innovations in oligonucleotide drug delivery.

Authors:  Melanie A Lysik; Susanna Wu-Pong
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.